Skip to main content

Table 2 Proportion of patients with HIV-1 RNA <400 copies/mL and <50 copies/mL

From: Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment

Week HIV-1 RNA <400 copies/mL, n/N (%)   HIV-1 RNA <50 copies/mL, n/N (%)
  ITT: Observed   ITT: M = F   ITT: Observed   ITT: M = F
  Abacavir PI   Abacavir PI   Abacavir PI   Abacavir PI
Baseline 52/52 (100) 52/52 (100)   52/52 (100) 52/52 (100)   42/52 (81) 47/52 (90)   42/52 (81) 47/52 (90)
4 49/49 (100) 44/45 (98)   49/52 (94) 44/52 (85)   48/49 (98) 43/45 (96)   48/52 (92) 43/52 (83)
8 39/42 (93) 42/42 (100)   39/52 (75) 42/52 (81)   38/42 (90) 40/42 (95)   38/52 (73) 40/52 (77)
12 38/41 (93) 40/40 (100)   38/52 (73) 40/52 (77)   38/41 (93) 39/40 (98)   38/52 (73) 39/52 (75)
20 38/41 (93) 40/40 (100)   38/52 (73) 40/52 (77)   32/41 (78) 38/40 (95)   32/52 (62) 38/52 (73)
28 36/40 (90) 40/40 (100)   36/52 (69) 40/52 (77)   32/40 (80) 39/40 (98)   32/52 (62) 39/52 (75)
  1. Abbreviations: ITT = intent to treat; M = F = missing equals failure analysis; PI = protease inhibitor.